KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Intangibles (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Intangibles for 14 consecutive years, with $502.1 million as the latest value for Q1 2025.

  • On a quarterly basis, Intangibles fell 13.39% to $502.1 million in Q1 2025 year-over-year; TTM through Mar 2025 was $502.1 million, a 13.39% decrease, with the full-year FY2024 number at $521.9 million, changed N/A from a year prior.
  • Intangibles was $502.1 million for Q1 2025 at Supernus Pharmaceuticals, down from $521.9 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $784.7 million in Q4 2021 to a low of $502.1 million in Q1 2025.
  • A 4-year average of $639.1 million and a median of $641.1 million in 2022 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: skyrocketed 115.37% in 2021, then decreased 13.39% in 2025.
  • Supernus Pharmaceuticals' Intangibles stood at $784.7 million in 2021, then fell by 10.48% to $702.5 million in 2022, then dropped by 25.7% to $521.9 million in 2024, then dropped by 3.79% to $502.1 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Intangibles are $502.1 million (Q1 2025), $521.9 million (Q4 2024), and $579.8 million (Q1 2024).